Key result
Omecamtiv mecarbil produced progressively greater reductions in heart failure events or cardiovascular death as baseline ejection fraction decreased (HR 0.83; 95% CI 0.73-0.95 for EF ≤22%).
Why the study?
The purpose of this study was to evaluate the influence of baseline ejection fraction on the therapeutic effect of omecamtiv mecarbil.
Does omecamtiv mecarbil reduce heart failure events or cardiovascular death in patients with heart failure and reduced ejection fraction, and how does baseline ejection fraction modify this effect?
RCT (n=8,256)
Yes
Does omecamtiv mecarbil reduce heart failure events or cardiovascular death in patients with heart failure and reduced ejection fraction, and how does baseline ejection fraction modify this effect?
Hazard Ratio: 0.83 (95% CI 0.73–0.95)
Absolute Risk Reduction: 7.4%
Number Needed to Treat: 11.8
p-value: p=0.004
Omecamtiv mecarbil provides progressively greater therapeutic benefit in reducing heart failure events or cardiovascular death in HFrEF patients as baseline ejection fraction decreases.
Favors omecamtiv mecarbil in severe HFrEF; extends RCT evidence of greater benefit at lower ejection fraction.
BACKGROUND: In GALACTIC-HF (Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure) (n = 8,256), the cardiac myosin activator, omecamtiv mecarbil, significantly reduced the primary composite endpoint (PCE) of time-to-first heart failure event or cardiovascular death in patients with heart failure and reduced ejection fraction (EF) (≤35%). OBJECTIVES: The purpose of this study was to evaluate the influence of baseline EF on the therapeutic effect of omecamtiv mecarbil. METHODS: Outcomes in patients treated with omecamtiv mecarbil were compared with placebo according to EF. RESULTS: The risk of the PCE in the placebo group was nearly 1.8-fold greater in the lowest EF (≤22%) compared with the highest EF (≥33%) quartile. Amongst the pre-specified subgroups, EF was the strongest modifier of the treatment effect of omecamtiv mecarbil on the PCE (interaction as continuous variable, p = 0.004). Patients receiving omecamtiv mecarbil had a progressively greater relative and absolute treatment effect as baseline EF decreased, with a 17% relative risk reduction for the PCE in patients with baseline EF ≤22% (n = 2,246; hazard ratio: 0.83; 95% confidence interval: 0.73 to 0.95) compared with patients with EF ≥33% (n = 1,750; hazard ratio: 0.99; 95% confidence interval: 0.84 to 1.16; interaction as EF by quartiles, p = 0.013). The absolute reduction in the PCE increased with decreasing EF (EF ≤22%; absolute risk reduction, 7.4 events per 100 patient-years; number needed to treat for 3 years = 11.8), compared with no reduction in the highest EF quartile. CONCLUSIONS: In heart failure patients with reduced EF, omecamtiv mecarbil produced greater therapeutic benefit as baseline EF decreased. These findings are consistent with the drug's mechanism of selectively improving systolic function and presents an important opportunity to improve the outcomes in a group of patients at greatest risk. (Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction [GALACTIC-HF]; NCT02929329).
No takes yet. Share an insight, caveat, or question.
Teerlink et al. (2021) conducted an RCT in Heart failure with reduced ejection fraction (n=8,256). Omecamtiv mecarbil vs. Placebo was evaluated on Time-to-first heart failure event or cardiovascular death (HR 0.83, 95% CI 0.73-0.95, p=0.004). Omecamtiv mecarbil produced progressively greater reductions in heart failure events or cardiovascular death as baseline ejection fraction decreased (HR 0.83; 95% CI 0.73-0.95 for EF ≤22%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: